Navigation Links
New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
Date:8/9/2010

INDIANAPOLIS Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.

The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

An estimated 3.2 million Americans and 170 million people worldwide are infected with the hepatitis C virus, but many do not know it. In the United States, 70 percent of affected individuals are infected with genotype 1 hepatitis C, the most difficult to treat. Although there may be no symptoms for years, long-term infection can cause cirrhosis and the disease is a leading cause of liver cancer and liver transplantation. Hepatitis C infections occur mainly through transmission of infected blood, such as via injection drug use, and there is no vaccine.

Currently fewer than half of patients with genotype 1 hepatitis C are treated effectively by the standard combination of two drugs, peginterferon alfa-2b plus ribavirin, which is typically given for 48 weeks. The treatment can be difficult for some patients due to anemia and other side effects.

Adding the drug boceprevir increased the cure rate to as high as 75 percent in those who received 48 weeks of the three-drug combination therapy, compared to 38 percent of those in the control group, who received the standard two-drug treatment for 48 weeks, said Dr. Kwo, associate professor of medicine at the IU School of Medicine. The two-year phase 2 trial was conducted at 67 sites with 520 patients in the U.S., Canada and Europe.

In the boceprevir study, known as the SPRINT-1 trial, researchers tested several different options to evaluate the effectiveness of the combination ther
'/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Longer Antiviral Therapy Reduces Lung Transplant Complications
2. Antiviral therapy during compensated cirrhosis most cost-effective approach
3. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
4. New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
5. Surgery better than radiation, hormone treatments for some prostate cancer, study shows
6. Women Can Safely Get Pregnant Right After Miscarriage, Study Shows
7. Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy
8. Epilepsy Drugs Dont Raise Suicide Risk, Study Shows
9. Iron-regulating protein is strong predictor of breast cancer prognosis, study shows
10. Brain study shows that thinking about God reduces distress -- but only for believers
11. Survey of coastal residents shows Gulf oil spill has significant impact on families
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... emerged among U.S. emergency rooms in recent years, according to the American Dental Association. ... number of dental emergency visits went from 1.1 million in a single year to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Illinois Health ... effective July 31. , The acquisition includes all of IBAM NA’s cyclotron sites ... to have both, a robust regionally located business, as well as a large manufacturing ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Constantin Vasilica, ... accompanied by tissue injury caused by diabetes after many years of suffering and using ... times, and he didn’t want to ask for extra time off or wait longer ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... medical information, risk management and investigative services, has introduced a new logo ... expert information solutions that improve business outcomes for its customers. EMSI’s new ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Inc. (NYSE: SRZ ) today announced that it will ... , As previously disclosed in its 2008 10-K, Sunrise could be ... failed to comply with their financial covenants in 2008. HCP ... , , "While we regret the loss of these communities, ...
... corporations and average citizens sending money to their favorite ... according to a new study by the Institute for ... Washington. The research shows that funding for health ... decades from $5.6 billion in 1990 to $21.8 ...
... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
... /PRNewswire/ -- Children,s Hospital Boston and CompuCyte ... Imaging Cytometry Center of Excellence in Boston, to be ... Children,s Hospital Boston and CompuCyte will create an educational ... using laser scanning cytometry in cell- and tissue-based research. ...
... quickly, experts say, , THURSDAY, June 18 (HealthDay News) -- ... 60 who are hoping for a kidney transplant will die ... study also found that other factors, such as having diabetes, ... or waiting for a transplant in certain areas of the ...
... PHILADELPHIA , June 18 ERT (Nasdaq: ... technology, ePRO, and other services to the biopharmaceutical, medical device, ... by ringing the famous NASDAQ bell. Joel Morganroth, Chairman of ... at ERT rang the NASDAQ MarketSite(R) closing bell in New ...
Cached Medicine News:Health News:Global health funding soars, boosted by unprecedented private giving 2Health News:Global health funding soars, boosted by unprecedented private giving 3Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:Children's Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center 2Health News:Children's Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center 3Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 2Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 3Health News:ERT Officials Ring the NASDAQ Closing Bell 2Health News:ERT Officials Ring the NASDAQ Closing Bell 3
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... (Nasdaq: PRGO ; TASE) today announced that ... calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a generic ... first to file on this product. Taclonex® ... treatment of psoriasis vulgaris in adults 18 years of ...
... NEW YORK, Feb. 22, 2011 Reportlinker.com announces ... in its catalogue: Global Pharmaceutical ... This report analyzes the worldwide ... by the following Dosage Forms: Injectables (Injections, Vials, ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3Reportlinker Adds Global Pharmaceutical Contract Manufacturing Industry 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: